Physician profile
Laura M Anderson
NPI 1336776350
$693.98
in general payments reported to CMS, 2019-2025
18 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.14 · 2024: $359 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $149.65 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $64.02 | 2024 | Xarelto |
| United Therapeutics Corporation | $49.94 | 2024-2025 | Tyvaso, Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $49.39 | 2025 | Eliquis, Camzyos |
| Smith+Nephew, INC. | $39.01 | 2023 | Grafix |
| Genzyme Corporation | $38.67 | 2025 | |
| Daiichi Sankyo INC. | $32.15 | 2024 | Injectafer |
| Novo Nordisk INC | $31.63 | 2024-2025 | Wegovy, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $31.10 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $27.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.29 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $25.73 | 2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $25.00 | 2025 | Onpattro |
| Heartflow, INC. | $24.72 | 2025 | |
| Edwards Lifesciences Corporation | $22.24 | 2025 | Sapien 3 Ultra Resilia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.28 | 2024 | Cardiomems |
| Amgen INC. | $19.66 | 2024 | Repatha |
| Pfizer INC. | $16.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.